Pancreatic Cancer Research

ResearcherKyorin UniversityActive in the last 2 years

Fumio Nagashima

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5940-4363; OpenAlex author ID A5034993620, A5129992825. Sources: OpenAlex.

Their work

Papers
14 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
1
Collaborators
41
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 3 papers · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 14

  1. Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II t… Co-author DOI 10.1186/s12885-026-15699-8↗
  2. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  3. A Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer Refractory to Gemcitabine Monotherapy. Co-author DOI 10.21873/anticanres.16919↗
  4. A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.9504-22↗
  5. The Prognostic Utility of a Geriatric Assessment for Patients with Pancreatic Cancer Receiving Gemcitabine-based Chemotherapy: A Prospective Observational Stud… Co-author DOI 10.2169/internalmedicine.9689-22↗
  6. Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-es… Co-author DOI 10.1016/j.ejca.2022.06.010↗
  7. Trends in the surgical treatment for pancreatic cancer in the last 30 years. Co-author DOI 10.5582/bst.2022.01250↗
  8. Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer. Co-author DOI 10.1016/s1470-2045(21)00489-7↗
  9. Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Panc… First author DOI 10.2169/internalmedicine.2362-18↗
  10. Emerging protein kinase inhibitors for treating pancreatic cancer. First author DOI 10.1080/14728214.2017.1293648↗
  11. Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refrac… Co-author DOI 10.1007/s00280-014-2665-8↗
  12. [Systemic chemotherapy for unresectable pancreatic cancer]. First author PMID 25857004↗
  13. [Chemoradiotherapy for Locally Advanced Pancreatic Cancer]. Co-author PMID 26489544↗
  14. Current status and future direction of chemotherapy for pancreatic cancer. First author DOI 10.3978/j.issn.2304-3865.2012.11.04↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junji Furuse · 12 shared papers, 2013–2026 · strength 1.66
  2. Naohiro Okano · 7 shared papers, 2015–2024 · strength 0.98
  3. Masafumi Ikeda · 3 shared papers, 2019–2026 · strength 0.42
  4. Hiroshi Kitamura · 3 shared papers, 2015–2023 · strength 0.35
  5. Masato Ozaka · 2 shared papers, 2022–2026 · strength 0.33
  6. Takuji Okusaka · 2 shared papers, 2022–2026 · strength 0.33
  7. Naoki Sasahira · 2 shared papers, 2022–2026 · strength 0.33
  8. Yoshihiro Sakamoto · 2 shared papers, 2022–2023 · strength 0.31
  9. Ryota Matsuki · 2 shared papers, 2022–2023 · strength 0.31
  10. Tatsuya Ioka · 2 shared papers, 2019–2026 · strength 0.29
  11. Makoto Ueno · 2 shared papers, 2019–2026 · strength 0.29
  12. Junichi Nakazawa · 1 shared paper, 2023 · strength 0.24
  13. Mariko Nishioka · 1 shared paper, 2024 · strength 0.23
  14. Satoaki Nakamura · 1 shared paper, 2026 · strength 0.20
  15. Kentaro Yamazaki · 1 shared paper, 2026 · strength 0.20
  16. Yusuke Sano · 1 shared paper, 2026 · strength 0.20
  17. Junki Mizusawa · 1 shared paper, 2026 · strength 0.20
  18. Yoshito Komatsu · 1 shared paper, 2026 · strength 0.20
  19. Satoshi Kobayashi · 1 shared paper, 2026 · strength 0.20
  20. Taro Yamashita · 1 shared paper, 2026 · strength 0.20
  21. Yukiko Takayama · 1 shared paper, 2026 · strength 0.20
  22. Kazuo Hara · 1 shared paper, 2026 · strength 0.20
  23. Masashi Kanai · 1 shared paper, 2026 · strength 0.20
  24. Ken Kamata · 1 shared paper, 2026 · strength 0.20
  25. Nao Fujimori · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.